{
  "id": "5c6548d4e842deac67000020",
  "type": "summary",
  "question": "What is CPX351?",
  "ideal_answer": "CPX-351, a novel liposomal formulation which encapsulates cytarabine and daunorubicin in 5:1 molar ratio, has shown promising efficacy, leading to recent US FDA approval for front-line therapy for patients with therapy-related AML and AML with myelodysplasia-related changes based on a large multicenter Phase III clinical trial.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29378418"
  ],
  "snippets": [
    {
      "text": "CPX-351, a novel liposomal formulation which encapsulates cytarabine and daunorubicin in 5:1 molar ratio, has shown promising efficacy, leading to recent US FDA approval for front-line therapy for patients with therapy-related AML and AML with myelodysplasia-related changes based on a large multicenter Phase III clinical trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29378418",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}